Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMJBZ8N)

Drug Name
Carbetapentane Drug Info
Synonyms
Carbetapentane citrate; Pentoxyverine citrate; 23142-01-0; Loucarbate; Pentoxiverine citrate; Carbetapentane citrate salt; Toclase; Toclase citrate; Carbetapentone citrate; Carbetapentane (citrate); UNII-4SH0MFJ5HJ; Carbetapentane citrate [NF]; EINECS 245-449-5; 4SH0MFJ5HJ; 2-(2-diethylaminoethoxy)ethyl 1-phenylcyclopentanecarboxylate citrate; 2-(2(Diethylamino)ethoxy)ethyl 1-phenyl-cyclopentanecarboxylate citrate (1:1); 2-(2-(Diethylamino)ethoxy)ethyl 1-phenylcyclopentyl-1-carboxylate dihydrogen citrate; Ethanol, 2-(2-(die
Cross-matching ID
PubChem CID
2562
ChEBI ID
CHEMBL73234
CAS Number
CAS 77-23-6
TTD Drug ID
D09VBC

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Base excision repair 2.02 9.33e-3 29/33 (87.88%) POLE2;PARP2;HMGB1;...
RNA polymerase 1.91 9.33e-3 23/31 (74.19%) POLR3K;POLR2I;POLR2L;...
Oxidative phosphorylation 1.87 1.24e-2 93/133 (69.92%) COX7B;NDUFC1;ATP6V0C;...
Phagosome -1.64 4.81e-2 118/152 (77.63%) MPO;DYNC1LI2;CYBB;...
Mucin type O-glycan biosynthesis -1.67 3.89e-2 20/36 (55.56%) C1GALT1;GALNT1;GCNT1;...
Th17 cell differentiation -1.69 3.29e-2 95/107 (88.79%) MTOR;CD3G;IFNG;...
Hematopoietic cell lineage -1.75 1.80e-2 90/99 (90.91%) IL1R2;FCGR1A;THPO;...
Ferroptosis -1.77 1.32e-2 36/41 (87.8%) MAP1LC3C;GCLC;ACSL6;...
Leishmaniasis -1.80 9.16e-3 67/77 (87.01%) JUN;CR1;TGFB2;...
NF-kappa B signaling pathway -1.80 9.06e-3 90/104 (86.54%) DDX58;RELB;TRAF1;...
Viral protein interaction with cytokine and cytokine re... -1.84 4.88e-3 84/100 (84%) PF4V1;LTBR;TNFRSF1B;...
Th1 and Th2 cell differentiation -1.86 2.64e-3 80/92 (86.96%) IL2RB;IL12B;CHUK;...
ABC transporters -1.87 2.88e-3 37/45 (82.22%) ABCC10;ABCC6;ABCC4;...
Cell adhesion molecules -1.89 3.17e-3 118/148 (79.73%) MPZL1;CDH2;ITGAL;...
Rheumatoid arthritis -1.94 1.17e-3 78/93 (83.87%) JUN;ITGAL;TGFB2;...
Autoimmune thyroid disease -2.09 0.00e+0 46/53 (86.79%) HLA-A;HLA-G;CGA;...
Legionellosis -2.10 0.00e+0 51/57 (89.47%) CR1;CXCL1;NAIP;...
Intestinal immune network for IgA production -2.13 0.00e+0 38/48 (79.17%) IL15RA;IL15;HLA-DOB;...
Antigen processing and presentation -2.13 0.00e+0 60/78 (76.92%) TAP2;HSPA8;CIITA;...
Type I diabetes mellitus -2.14 0.00e+0 38/43 (88.37%) IL1A;HLA-A;HLA-G;...
Allograft rejection -2.22 0.00e+0 32/38 (84.21%) HLA-A;HLA-G;HLA-B;...
Graft-versus-host disease -2.23 0.00e+0 32/42 (76.19%) IL1A;HLA-A;HLA-G;...
Inflammatory bowel disease -2.24 0.00e+0 58/65 (89.23%) IL2RG;JUN;TGFB2;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 10uM 6H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.37uM - 10uM 6H, 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 10uM 24H